Kevin Pojasek
Fondatore presso Catamaran Bio, Inc.
Provenienza dei contatti di primo grado di Kevin Pojasek
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London.
35
| Holding Company | Investment Managers | 35 |
Catamaran Bio, Inc.
 Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware.
7
| Holding Company | Financial Conglomerates | 7 |
Enara Bio Ltd.
2
| Holding Company | Biotechnology | 2 |
Amathus Therapeutics, Inc.
 Amathus Therapeutics, Inc. Investment ManagersFinance Amathus Therapeutics, Inc. engages in the development of small-molecule therapeutics for enhanced mitochondrial function for treatment lysosomal-storage disorders and neurodegenerative diseases. The company is headquartered in Cambridge, MA.
1
| Extinct | Investment Managers | 1 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Kevin Pojasek tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| University of Cambridge | College/University | Graduate Degree Undergraduate Degree Doctorate Degree Graduate Degree | |
Sitryx Therapeutics Ltd.
 Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Medical Specialties | Director/Board Member Director/Board Member Founder Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Operating Officer Private Equity Investor | |
Therini Bio, Inc.
 Therini Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Therini Bio, Inc. engages in research and development in the field of biotechnology. The company was founded by Katerina Akassoglou in 2016 and is headquartered in San Francisco, CA. | Miscellaneous Commercial Services | Chairman Chairman Director/Board Member | |
| RUBIUS THERAPEUTICS | Biotechnology | General Counsel Director/Board Member Chief Tech/Sci/R&D Officer | |
| University of Oxford | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
SV Health Managers LLP
 SV Health Managers LLP Investment ManagersFinance SV Health Managers LLP (SVHM) is the investment management subsidiary of SV Life Sciences Advisers LLP in the UK. Established in 2005, the firm was formerly known as SV Life Sciences Managers LLP and changed their name to SV Health Managers LLP in 2017. Based in London, the firm manages the International Biotechnology Trust plc (LSE: IBT), an investment trust vehicle listed on the London Stock Exchange into which corporate and private investors may invest. | Investment Managers | Chief Executive Officer Portfolio Manager-Equities | |
Cellinta Ltd.
 Cellinta Ltd. Investment ManagersFinance Cellinta Ltd. operates as a biotechnology firm. The company was founded on August 16, 2019 and is headquartered in Reading, the United Kingdom. | Investment Managers | Director/Board Member Director/Board Member | |
Autifony Therapeutics Ltd.
 Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Imbria Pharmaceuticals, Inc.
 Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
LSV CAPITAL MANAGEMENT LLC
 LSV CAPITAL MANAGEMENT LLC Investment ManagersFinance LSV Capital Management LLC (Lightstone Ventures) is a venture capital firm founded in 2012. The firm is headquartered in Menlo Park, California. | Investment Managers | Consultant / Advisor Private Equity Investor | |
Kesios Therapeutics Ltd.
 Kesios Therapeutics Ltd. BiotechnologyHealth Technology Kesios Therapeutics Ltd. provides biotechnology services. It develops novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs. The company was founded by Menotti Ruvo, Laura Tornatore, and Guido Franzoso on July 13, 2012 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
Zarodex Therapeutics Ltd.
 Zarodex Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Zarodex Therapeutics Ltd. engages in the research and experimental development on biotechnology. The company was founded on July 26, 2017 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Ervaxx Ltd.
 Ervaxx Ltd. Pharmaceuticals: MajorHealth Technology Ervaxx Ltd. is a British company that pioneers the use of dark antigens to deliver targeted immunotherapies for treating and preventing cancer. The company was founded in 2016 by George Kassiotis, Drew M. Pardoll and is based in London, UK. The company's powerful, proprietary edapt platform has been developed to discover and validate dark antigens providing an in-depth assessment of candidate antigens on primary tumor cells along with their immunogenic potential. Ervaxx is advancing a pipeline of T cell receptor-based therapies, off-the-shelf cancer vaccines, and other immunotherapies leveraging these insights into the role of dark antigens in cancer. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Alchemab Therapeutics Ltd.
 Alchemab Therapeutics Ltd. BiotechnologyHealth Technology Alchemab Therapeutics Ltd. engages in developing of antibodies. It focuses on discovering and developing novel therapeutics for patients. The company was founded in 2019 and is headquartered in Kings Cross, the Unite Kingdom. | Biotechnology | Director/Board Member Founder | |
Cybele Therapeutics Ltd.
 Cybele Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Cybele Therapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 23, 2019 and is headquartered in Reading, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Mestag Therapeutics Ltd.
 Mestag Therapeutics Ltd. Financial ConglomeratesFinance Mestag Therapeutics Ltd. is engaged in the biotechnology industry. The company was founded on February 17, 2020 and is headquartered in Cambridge, the United Kingdom. | Financial Conglomerates | Director/Board Member Founder | |
Loqus23 Therapeutics Ltd.
 Loqus23 Therapeutics Ltd. BiotechnologyHealth Technology Loqus23 Therapeutics Ltd.engages in research and development of biotechnology. The company was founded on March 29, 2019 and is headquartered in in Reading, the United Kingdom. | Biotechnology | Director/Board Member Chief Executive Officer | |
Cell Medica Switzerland AG
 Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Transine Therapeutics Ltd.
 Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Eyebiotech Ltd.
 Eyebiotech Ltd. BiotechnologyHealth Technology Eyebiotech Ltd. is a British clinical stage ophthalmology company that treats patients with sight-threatening diseases. The company is based in London, UK. Eyebiotech was founded in 2021 by David R. Guyer and Anthony P. Adamis. David R. Guyer has been the CEO since 2021. | Biotechnology | Director/Board Member Chairman | |
Endlyz Therapeutics, Inc.
 Endlyz Therapeutics, Inc. BiotechnologyHealth Technology Endlyz Therapeutics, Inc. is an American company that operates in the biotechnology industry. | Biotechnology | Director/Board Member Director/Board Member | |
Karus Therapeutics Ltd.
 Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Chairman Director/Board Member | |
| University of London | College/University | Doctorate Degree Doctorate Degree | |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal | |
Weatherden Ltd.
 Weatherden Ltd. BiotechnologyHealth Technology Weatherden Ltd. is a pioneering clinical development consulting group based in London, UK. The British company specializes in scientific strategy, translational medicine, clinical development, diligence preparation, and support for M & A. Weatherden focuses on de-risking programs early and optimizing clinical, regulatory, and commercial pathways to bring life-changing medicines to patients. With over 750 years of combined industry experience, they are dedicated to improving the chances for breakthrough therapies to address unmet clinical needs. The private company, founded by Duncan McHale and Houman Ashrafian, provides trusted advice to biopharma, funds, startups, spin-outs, and nonprofits. Emma Tinsley has been the CEO of the company since 2017. | Biotechnology | Founder Chief Executive Officer | |
| Stanford University | College/University | Graduate Degree Undergraduate Degree | |
| Vanderbilt University | College/University | Undergraduate Degree Undergraduate Degree | |
| The Wharton School of the University of Pennsylvania | College/University | Undergraduate Degree Masters Business Admin | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree | |
| TRAVERE THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Kellogg School of Management | College/University | Masters Business Admin | |
| The Open University | College/University | Masters Business Admin | |
| The University of Alabama School of Medicine | College/University | Doctorate Degree | |
Enzyvant, Inc.
 Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Pharmaceuticals: Major | Chief Executive Officer | |
Disarm Therapeutics, Inc.
 Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Biotechnology | Chief Executive Officer | |
| THERAVANCE BIOPHARMA, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Reacta Biotech Ltd.
 Reacta Biotech Ltd. Miscellaneous Commercial ServicesCommercial Services Reacta Biotech Ltd. engages in a biotechnology company. It develops, manufactures, and commercializes oral food challenge materials to pharmaceuticals standards of Good Manufacturing Practice (GMP). The company was founded by Clare Mills, Ashley Woodcock, and Peter McPartland in June 2013 and is headquartered in Deeside, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| INNOVIVA, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| AIMMUNE THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Dualitas Ltd.
 Dualitas Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Envisics LLC, Dualitas Ltd. is a British company that engages in developing technologies to deliver holographic and augmented reality products and services. The company is based in London, UK. The company was founded in 2016 by Houman Ashrafian. | Miscellaneous Commercial Services | Founder | |
Aravax Pty Ltd.
 Aravax Pty Ltd. BiotechnologyHealth Technology Aravax Pty Ltd. develops treatments for peanut allergies. The company was founded in May 2015 and is headquartered in Melbourne, Australia. | Biotechnology | Director/Board Member | |
ReViral Ltd.
 ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Chief Tech/Sci/R&D Officer |
Statistiche
Distribuzione geografica
| Regno Unito | 24 |
| Stati Uniti | 23 |
| Irlanda | 3 |
| Svizzera | 3 |
| Australia | 2 |
Settori
| Health Technology | 28 |
| Consumer Services | 11 |
| Commercial Services | 9 |
| Finance | 6 |
Posizioni
| Director/Board Member | 151 |
| Corporate Officer/Principal | 61 |
| Private Equity Investor | 47 |
| Undergraduate Degree | 24 |
| Chairman | 23 |
Contatti più connessi
| Insiders | |
|---|---|
| Kate Bingham | 31 |
| Maina Bhaman | 26 |
| Houman Ashrafian | 22 |
| Erik Lium | 17 |
| Ruth McKernan | 16 |
| Allan W. May | 16 |
| Hamish Alan Cameron | 14 |
| Graham J. Boulnois | 14 |
| Anne Prener | 14 |
| Peter DiLaura | 13 |
| Frank Lee | 13 |
| Mark F. Boshar | 13 |
| Bob Ang | 12 |
| Jamie Kasuboski | 12 |
| Aaron Sandoski | 12 |
- Borsa valori
- Insiders
- Kevin Pojasek
- Connessioni Società
